摘要
目的观察普米克令舒联合利巴韦林雾化吸入治疗小儿毛细支气管炎的疗效。方法选择该院2010年9月—2012年2月住院治疗的毛细支气管炎患儿92例分为对照组(n=46)与观察组(n=46),对照组应用利巴韦林雾化吸入治疗,观察组应用普米克令舒联合利巴韦林雾化吸入治疗,7d为1个疗程,观察比较两组患儿的临床症状改善情况、治疗效果及不良反应。结果观察组咳嗽消失时间、憋喘消失时间、肺部哮鸣音消失时间均短于对照组,两组比较差异有统计学意义(P<0.05)。观察组总有效率为91.30%,对照组总有效率为78.26%,两组总有效率比较,差异有统计学意义(P<0.05)。两组均未出现明显不良反应。结论普米克令舒联合利巴韦林雾化吸入治疗小儿毛细支气管炎疗效显著,不良反应少,值得临床推广使用。
Objective To observe the clinical efficacy of atomization inhalation of pulmicort respules combined with ribavirin in treatment of bronchiolitis in children. Methods 92 children with bronchiolitis hospitalized in our hospital from Sep. 2010 to Feb. 2012 were divided into ocontrol group and observation group with 46 cases in each group. The control group was given ribavirin atomization inhalation and the observation group was treated with pulmicort respules combined with ribavirin. 7 days was a course of treatment. The clinical symptoms, treatment effectiveness and side effects were observed and compared between the two groups. Results The duration of symptoms and signs in the observation group, including cough, gasping and wheezing rale were significantly shorted than those in the control group（P 0.05）. The total effective rate of the observation group was significant higher than that of the control group （91.30% Vs. 78.26% , P0.05）. There were no significant difference of adverse reactions in the two groups. Conclusion Atomization inhalation of pulmicort respules combined with ribavirin is effective in treating bronchiolitis in children with fewer adverse reactions,which is worthy of clinical use.
出处
《中外医疗》
2012年第35期7-8,共2页
China & Foreign Medical Treatment
